Age for HPV vaccination

Vaccine

Volumn 26, Issue SUPPL. 1, 2008, Pages

  Harper, Diane M ^a   Paavonen, Jorma ^b  

^a DARTMOUTH COLLEGE   (United States)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Age; Cervical cancer; HPV vaccination; Prevention; Prophylactic vaccination

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ARTICLE; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER SCREENING; DRUG EFFICACY; DRUG SAFETY; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOGENICITY; INFECTION RATE; INFECTION RISK; NONHUMAN; PAPANICOLAOU TEST; PRECANCER; PRIORITY JOURNAL; SEROCONVERSION; UTERINE CERVIX CANCER; VACCINATION AGE; VERRUCA VULGARIS;

AGE FACTORS; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TIME FACTORS; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 39749122144     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.01.013     Document Type: Article

References (46)

1. Stanley M.A. Human papillomavirus vaccines. Rev Med Virol 16 3 (2006) 139-149
2. Ho G.Y.F., Studentsov Y.Y., Bierman R., and Burk R.D. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 13 (2004) 110-116
3. Insinga R.P., Dasbach E.J., and Myers E.R. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 36 11 (2003) 1397-1403
4. Rintala M.A.M., Grenman S.E., Jarvenkyla M.E., Syjanen K.J., and Syrjanen S.M. High risk types of human papillomavirus (HPV) DNA in oral and genital mucosa of infants during their first 3 years of life: experience from the Finnish HPV family study. Clin Infect Dis 41 (2005) 1728-1733
5. Watts D.H., Koutsky L.A., Holmes K.K., Goldman D., Kuypers J., Kiviat N.B., et al. Low risk of perinatal transmission of human papillomavirus: results from a prospective cohort study. Am J Obstet Gynecol 178 (1998) 365-373
6. Smith E.M., Ritchie J.M., Yankowitz J., Swarnavel S., Wang D., Haugen T.H., et al. Human papillomavirus prevalence and types in newborns and parents; concordance and modes of transmission. Sex Transm Dis 31 (2004) 57-62
7. Antonsson A., Karanfilovska S., Lindqvist P.G., and Hannson B.G. General acquisition of human papillomavirus infections of skin occurs in early infancy. J Clin Microbiol 41 (2003) 2509-2514
8. Powell J., Strauss S., Gray J., and Wojnarowska F. Genital carriage of human papillomavirus (HPV) DNA in prepubertal girls with and without vulval disease. Pediatr Dermatol 20 (2003) 191-194
9. Cason J., Rice P., and Best J.M. Transmission of cervical cancer-associated human papilloma viruses from mother to child. Intervirology 41 (1998) 213-218
10. Cason J., Kaye J.N., Jewers R.J., Kambo P.K., Bible J.M., Kell B., et al. Perinatal infection and persistence of human papillomavirus types 16 and 18 in infants. J Med Virol 47 (1995) 209-218
11. Stone K.M., Karem K.L., Sternberg M.R., McQuillan G.M., Poon A.D., Under E.R., et al. Seroprevalence of human papillomavirus type 16 infection in the United States. JID 186 (2002) 1396-1402
12. Marais D., Rose R.C., Lane C., Aspinall S., Bos P., and Williamson A.-L. Seroresponse to virus-like particles of human papillomavirus types 16, 18, 31, 33, and 45 in San people of Southern Africa. J Med Virol 60 (2000) 331-336
13. Dunne E.F., Karem K.L., Sternberg M.R., Stone K.M., Unger E.R., Reeves W.C., et al. Seroprevalence of human papillomavirus type 16 in children. JID 191 (2005) 1817-1819
14. Cubie H.A., Plumstead M., Zhang W., de Jesús O., Duncan L.A., and Stanley M.A. Presence of antibodies to human papillomavirus virus-like particles (VLPs) in 11-13 year old schoolgirls. J Med Virol 56 (1998) 210-216
15. The 3rd National Incidence Study of Child Abuse and Neglect. US Department of Health and Human Services, administration for children and families. National clearinghouse on child abuse and neglect, April 10, 2000. In: Sedlak A. A history of the national incidence study of child abuse and neglect. Sponsored by children's bureau, administration of children, youth and families, administration for children and families. U.S. Department of Health and Human Services, Washington, DC. Contract No. HHS-100-97-0017; February 21, 2001.
16. Schiffman M.H., Bauer H.M., Hoover R.N., Glass A.G., Cadell D.M., Rush B.B., et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. JNatl Cancer Inst 85 12 (1993) 958-964
17. Thompson D.L., Douglas J.M., Foster M., Hagensee M.E., DeGuiseppi C., Baron A.E., et al., for the Project RESPECT Study Group. Seroepidemilogy of infection with human papillomavirus 16, in men and women attending sexually transmitted disease clinics in the United States. JID 190 (2004) 1563-1574
18. Burchell A.N., Winer R.L., de Sanjose S., and Franco E.L. Epidemiology and transmission dynamics of genital HPV infection [Chapter 6]. Vaccine 24 S3 (2006) 52-61
19. Dunne E.F., Unger E.R., Stemberg M., McQuillan G., Swan D.C., Patel S.S., et al. Prevalence of HPV infection among females in the United States. JAMA 297 (2007) 813-819
20. Smith E.M., Johnson S.R., Ritchie J.M., Feddersen D., Wang D., Turek L.P., et al. Persistent HPV infection in postmenopausal age women. Int J Gynecol Obstet 87 (2004) 131-137
21. Castle P.E., Schiffman M., Herrero R., Hildesheim A., Rodriguez A.C., Bratti M.C., et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. JID 191 (2005) 1808-1816
22. Grainge M.J., Seth R., Guo L., Neal K.R., Coupland C., Vryenhoef P., et al. Cervical human papillomavirus screening among older women. Emerg Infect Dis 11 (2005) 1680-1685
23. Khan M.J., Castle P.E., Lorincz A.T., Wacholder S., Sherman M., Scott D.R., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. JNatl Cancer Inst 97 14 (2005) 1072-1079
24. Viscidi R.P., Schiffman M., Hildesheim A., Herrero R., Castle P.E., Bratti M.C., et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 13 2 (2004) 324-327
25. Mao C., Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Wiley D.J., et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia. A randomized controlled trial. Obstet Gynecol 107 (2006) 18-27
26. Wright Jr. T.C., and Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med 348 (2003) 6. l http://www.nejm.org
27. Surveillance, Epidemiology, and End Results (SEER) Program. Public-use data (1973-2000). In: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. Released April 2003.
28. Bosch F.X., de Sanjose S., Castellsague X., Moreno V., and Munoz N. Epidemiology of human papillomavirus infections and associations with cervical cancer: new opportunities for prevention. In: Campo M.S. (Ed). Papillomavirus research (2006), Caister Academic Press [Chapter 3]
29. Parkin D.M., and Bray F. The burden of HPV-related cancers [Chapter 2]. Vaccine 24S3 (2006) S3/11-S3/25
30. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 (2005) 271-278
31. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., Iversen O.E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95 11 (2006) 1459-1466 [Epub 2006, Nov 21]
32. Villa L.L., Ault K.A., Giuliano A.R., Costa R.L., Petta C.A., Andrade R.P., et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 24 27-28 (2006) 5571-5583 [Epub 2006, May 15]
33. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al., for the GlaxoSmithKline HPV Vaccine Trial Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 (2004) 1757-1765
34. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.-B., Romanowski B., Roteli-Martins C.M., et al., on behalf of the HPV Vaccine Trial Group. Sustained efficacy up to 4.5 years of a bivalent L1 virus like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised controlled trial. Lancet 367 (2006) 1247-1255
35. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Females united to unilaterally reduce endo/ectocervical disease (FUTURE) I investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356 19 (2007) 1928-1943
36. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356(19):1915-27.
37. Schwarz TF. Human papillomavirus (HPV) 16/18 L1 AS04 virus-like particle (VLP) cervical cancer vaccine is immunogenic and well -tolerated 24 months after vaccination in women up to age 55 years. ASCO June 5, 2007.
38. Gall S, Teixeira J, Wheeler C, Naud P, Harper DM, Franco EL, et al. Continued protection up to 5.5 years against HPV 16/18 infection and precancerous lesions in women vaccinated with the HPV 16/18 AS04 vaccine. On behalf of the HPV Vaccine Study group. Presented AACR 2007. Abstract 4900.
39. Olsson S.E., Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Malm C., et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25 26 (2007) 4931-4939
40. Ault K.A., and Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369 9576 (2007) 1861-1868
41. Hildesheim A., Herrero R., Wacholder S., Rodriguez A.C., Solomon D., Bratti M.C., et al., for the Costa Rican HPV Vaccine Trial Group. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298 7 (2007) 743-753
42. French K.M., Barnabas R.V., Lehtinen M., Kontula O., Pukkala E., Dillner J., et al. Strategies for the introduction of human papillomavirus vaccination: modeling the optimum age- and sex-specific pattern of vaccination in Finland. Br J Cancer 96 (2007) 514-518. http://www.bjcancer.com 10.1038/sj.bjc.6603575
43. Brisson M., Van de Velde N., De Wals P., and Boily M.C. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 25 29 (2007) 5399-5408
44. Joura E.A., Leodolter S., Hernandez-Avila M., Wheeler C.M., Perez G., Koutsky L.A., et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369 9574 (2007) 1693-1702
45. Kalliala I., Anttila A., Pukkala E., and Nieminen P. Risk of cervical and other cancers after treatment of CIN: retrospective cohort study. BMJ 331 (2005) 1183-1185
46. Edgren G., and Sparen P. Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population-based study. Lancet Oncol 8 (2007) 311-316